Synchrony Bio Leadership

Our Managing Directors have over 70 years of combined experience as founders, investors, executives and advisors in biomedical and life science startups as well as large industry experience.

Managing Directors:

Otis Carter

Otis is a Managing Director of Synchrony Bio and has 15 years of private equity and venture capital experience and has held a number of senior leadership positions.  Most recently, he served as General Counsel for a portfolio company of two leading New York-based Private Equity funds, helping grow the company revenue from $900 million to over $2.1 billion over a 5-year period, while leading the company’s M&A activities.

Prior to that, he served as Managing Director and General Counsel to a family office, helping establish the firm’s growth equity investment activities.  He began his career as a private equity attorney with the Chicago offices of Kirkland & Ellis LLP and Ropes & Gray LLP. He was named a 2013 Super Lawyers Rising Star in Mergers & Acquisitions.

Otis received his J.D. from Washington University in St. Louis, B.A. from Illinois Wesleyan University, and is currently finishing his MBA at The Wharton School at the Univ. of Pennsylvania.

Chad Stiening

Chad is a Managing Director of Synchrony Bio.  He is the CEO of Kypha, Inc., an immune monitoring diagnostics company focused on improving the management of autoimmune and inflammatory diseases.  He co-founded and serves as a Managing Director of Common Place Holdings, a life science venture formation and seed capital firm.

Chad was the 2013 Missouri Entrepreneur of the Year, and has served as an Entrepreneur-in-Residence at BioGenerator and the University of Illinois Urbana-Champaign Research Park.  Chad routinely serves on local and regional panels and strategic focus groups related to innovation and entrepreneurship.

He previously held positions as Executive Director of New Business Development at Nucleus, a private, university-affiliated research park and innovation entity; and prior to that, Chief of Translational Research Advancement at the Cardiovascular Innovation Institute in Louisville, KY.  He completed his doctorate in genetics and postdoctoral training in biomedical engineering at the University of Arizona.

Charlie Bolten

Charlie is a Managing Director of Synchrony Bio. He is a Vice President of BioGenerator, a seed stage investment group in St. Louis, and typically invests at the founding stage of new technology companies and serves on their boards of directors.

Representative investments for Charlie at BioGenerator include Arch Oncology, Confluence Life Sciences, Indalo Therapeutics, MediBeacon, Arvegenix, Adarza Biosystems, SentiAR, Unleash Immuno Oncolytics, and Canopy Biosciences. Charlie was previously a Principal Scientist and Project Leader in the Pfizer Exploratory Immunobiology group.

Before Pfizer, Charlie worked on pharma project teams in various therapeutic areas at Pharmacia and Searle, as well as in technology and screening groups. Charlie began his career in agricultural research at Monsanto, mainly in the area of genomics.

Alan Rathjen

Alan is a Principal at Synchrony Bio. He has a diverse background in life sciences and project management. His prior research experience included work on the underlying mechanisms of Parkinson’s disease at University of Wisconsin medical school.

Alan served as an officer in the United States Air Force. He is an Evaluator Pilot with over 190 combat aeromedical evacuation missions flown. He oversaw plans and policy for thirteen thousand personnel.  He has an MBA from Olin Business School at Washington University in St. Louis.

Venture Partners:

James Merselis

Jim is a Venture Partner of Synchrony Bio and Managing Director of Fund I. He has more than forty years of experience in healthcare, including twenty-two at Boehringer Mannheim Diagnostics (Roche Diagnostics). He led several healthcare diagnostic start-ups and has been a Non-executive director of Trinity Biotech since February 2009.

He is also a non-executive director of Kypha Inc.; a St. Louis, Missouri based immune monitoring diagnostics company focused on improving the management of autoimmune and inflammatory diseases, and Abram Scientific Inc.; a coagulation diagnostics company located in Palo Alto, California.

Jim also served as President and CEO of HemoSense, Inc., a point-of-care diagnostics company providing patients and physicians with rapid test results to help manage the risk of stroke with the use of Warfarin or Coumadin. During this time, Jim successfully took the company public (AMEX:HEM) followed two years later by its acquisition by Alere (NYSE:ALR).  His leadership at other start-ups has included: Nexus Dx (now Samsung), Alverix, Inc. (now Becton Dickenson) , and Micronics, Inc. (now SONY).

Paul Olivo

Paul is a Venture Partner of Synchrony Bio and Managing Director of Fund I. He holds the same position with Common Place Holdings, a life science venture formation and seed capital firm. He is the inventor of multiple U.S. and foreign patents and has extensive experience in the development of medical diagnostic tests.

Paul is former Senior Medical Director of Quidel Corporation. Prior to joining Quidel, he was Senior Vice President of R&D at Diagnostic Hybrids, Inc. where he played a significant role managing the company’s pipeline and intellectual property during Quidel’s acquisition of the company. Paul was also President and CSO of Apath where he led a successful effort to license Apath’s key hepatitis C virus technology to multiple pharmaceutical companies that led to the development of multiple therapeutic drugs for HCV hepatitis.

He is a licensed physician and board-certified Internist. Paul completed his Internal Medicine training at the University of Wisconsin where he was chief medical resident. He completed postdoctoral training at the National Institute of Allergy and Infectious Diseases at the NIH.  He serves as an adjunct member of the faculty in Molecular Microbiology at Washington University Medical School.